Reported Earlier, Bristol Myers Squibb Presents 3.5-Year Data on CAMZYOS at ESC 2024
Reported Earlier, Bristol Myers Squibb Presents 3.5-Year Data on CAMZYOS at ESC 2024
Bristol Myers Squibb (NYSE:BMY) today announced new long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study evaluating CAMZYOS (mavacamten) in adult patients with New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
今日,百时美施贵宝(纽交所:BMY)宣布了MAVA-Long-Term Extension(LTE)研究的EXPLORER-LTE队列的新的长期跟踪结果,评估了CAMZYOS(mavacamten)用于纽约心脏协会(NYHA)II-III级症状性梗阻性肥厚型心肌病(oHCM)的成年患者。
The long-term follow-up efficacy and safety data, presented today at the European Society of Cardiology (ESC) Congress in London, reinforce the established efficacy and safety profile of CAMZYOS, a first-in-class cardiac myosin inhibitor. With inclusion in both the ESC and AHA/ACC clinical guidelines as a recommended option for when symptoms persist after first-line therapy, CAMZYOS is a standard of care for symptomatic oHCM.
今天在伦敦举行的欧洲心脏学会(ESC)大会上,长期跟踪的疗效和安全性数据表明,CAMZYOS作为一种首创的心脏肌球蛋白抑制剂,加强了其已建立的疗效和安全性。在ESC和AHA/ACC临床指南中被纳入推荐方案,用于在一线治疗后症状持续存在时,CAMZYOS是对症状性oHCm的标准化治疗。
Patients experienced consistent and sustained improvements in echocardiographic measures and biomarkers after up to 3.5 years (180 weeks) of continuous treatment, including resting left ventricular outflow tract (LVOT) gradient, Valsalva LVOT gradient, left atrial volume index and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels. They also experienced an improvement in symptoms and functional capacity as measured by NYHA class and patient-reported outcomes, including most patients achieving NYHA class I. The safety profile of CAMZYOS for up to 3.5 years remained consistent with the established safety profile, with no new safety signals identified.
在持续治疗长达3.5年(180周)后,患者在超声心动图测量和生物标志物方面持续和一致地改善,包括安静时左室流出道(LVOT)梯度、Valsalva LVOt梯度、左房容积指数和N-末端前B型利钠肽(Nt-proBNP)水平。他们还通过NYHA分级和患者报告的结果体验到症状和功能能力的改善,包括大多数患者达到NYHA I级。CAMZYOS长达3.5年的安全性和已建立的安全性保持一致,未发现新的安全信号。